GlaxoSmithKline Boosts Its Cancer Drug Pipeline

GlaxoSmithKline Boosts Its Cancer Drug Pipeline

by | Dec 13, 2018 11:50 am | Pharmaceuticals

British drug giant GlaxoSmithKline (NYSE: GSK) has entered a new oncology arena with its acquisition of Tesaro Inc. (NASDAQ: TSRO) for approximately $5.1 billion. Tesaro is a commercial-stage biopharmaceutical company whose major marketed product, Zejula (niraparib), an oral poly ADP ribose polymerase (PARP) inhibitor, is currently approved for use in ovarian cancer. Specifically, it is in use in the United States and Europe as a treatment for adulta patients with recurrent ovarian cancer who are in response to platinum-based chemotherapy, regardless of BRCA gene mutation or biomarker status. More tests are under way to assess its use in “all-comers” patient populations, as a... Read More »